Medela Expands Negative Pressure Wound Therapy Product Solutions with New Integrated Dressing

Backed by decades of expertise, the unique sterile dressing innovation extends Medela’s full-system solution, maximizing patient comfort and improving outcomes for healthcare professionals

Medela, the healthcare choice for more than six million hospitals around the world*, announced today that it will introduce a new innovative sterile dressing within its negative pressure wound therapy (NPWT) portfolio in September. The Invia® Integrated Dressing is indicated for all wound types, including closed surgical incision, and can be used in the hospital or home setting, for up to seven days.

“We are thrilled to support the needs of our customers across the USA by introducing our Integrated Dressing,” explains Annette Brüls, CEO of Medela. “Backed by more than six decades of expertise in medical vacuum technology, this long-awaited product will be available in September as an extension of our full-system solution to support wound healing. When we set out to support this category, we applied our research-based suction technology to our negative pressure wound therapy solutions, and we’ve found that this provides an optimal environment for confident and effective wound healing.”

The Invia Integrated Dressing received FDA approval in July and is designed to work with Medela NPWT pumps, Liberty® and MotionTM, which work to maintain even pressure while pulling fluid away and keeping it off the wound site to support healing. The Integrated Dressing is a ‘peel-and-stick’ adhesive, comprised of a three-layer fluid handling pad that features a skin-friendly silicone adhesive border. The Integrated Dressing also includes a Quick-connector, common across the Medela NPWT portfolio for familiar pump-to-dressing connection, which offers clinician convenience while maximizing patient confidence and comfort.

With decades of expertise in medical vacuum technology, Medela’s NPWT solutions integrate Intelligent Pressure Control to ensure consistent and even pressure is delivered directly to the wound site, to promote the body’s natural wound healing and tissue regeneration process.

The Medela system also includes Dynamic Exudate Removal technology featuring double-lumen tubing to prevent blockages, efficiently remove exudate, and dynamically adapt to fluid fluctuations to pull fluid away from the wound and into the canister while allowing the body to continue its natural wound healing and tissue regeneration process.

The whole NPWT Innovation system solution is further informed by feedback from customers and healthcare professionals to include:
Whisper-quiet suction technology, minimizing disturbances during therapy
Compact and lightweight design that maximizes patient comfort and mobility
Award-winning support from our in-house customer excellence team
Straightforward pricing structure for increased accessibility and better transparency through predictable month-to-month spend that reduces administrative burdens and lowers cost without impacting patient care

To help users get started, Medela’s negative pressure wound therapy system includes comprehensive support for clinicians and patients, including on-site clinical in-servicing and training, instructional videos for staff and patients, and product tutorials supported by clinical education experts. Medela pumps are equipped with a QR code for product support and troubleshooting. For continued education, support videos are accessible via the free Medela NPWT app and online. As part of the company’s commitment to education, Medela offers complimentary professional continuing education courses on NPWT through Medela University. To learn more about Medela’s complete negative wound pressure therapy system, visit medelahealthcare.com or fill out the online form to receive information, or visit the Medela booth at the SAWC Fall Conference in November in Las Vegas.

SourceMedela

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”